Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
A forensic read on INTEGRA LIFESCIENCES HOLDINGS CORP built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
C · Mixed — selective
Forensic grade
Grey Zone
Financial health
1.2
Altman Z-score
Clean
Earnings quality
3
Forensic signals
-47.6%
ROE
$1.5B
Market cap
INTEGRA LIFESCIENCES HOLDINGS CORP earns a C (Mixed — selective) forensic quality grade, and its Altman Z-score is 1.2, placing it in the Grey zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-13%Return on invested capital.Return on invested capital is -13% and slipping from 6% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
224dInventory days.Days inventory outstanding moved from 215 to 224 FY2024→FY2025 (against cost of goods sold; inventory +15% vs +10% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
$511MGoodwill impairments.Took $511M of goodwill writedowns across 1 year(s) (FY2025 ($511M)). Writedowns mean past acquisitions underperformed what was paid for them — worth weighing on capital-allocation skill.
Key fundamentals
Net Margin-31.6%
Debt / Equity0.70x
Free Cash Flow$-31.1M
Latest Revenue$1.64B
Return on Equity-49.5%
Revenue Growth YoY+1.5%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on INTEGRA LIFESCIENCES HOLDINGS CORP:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about IART's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown